Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018;392:2052–90.

Article  Google Scholar 

Pilleron S, Sarfati D, Janssen-Heijnen M, Vignat J, Ferlay J, Bray F, et al. Global cancer incidence in older adults, 2012 and 2035: a population-based study. Int J Cancer. 2019;144:49–58.

Article  CAS  Google Scholar 

Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005;23:3112–24.

Article  Google Scholar 

Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–7.

Article  CAS  Google Scholar 

Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21:1383–9.

Article  Google Scholar 

Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626–31.

Article  Google Scholar 

Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schäfer P, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol. 2003;21:3580–7.

Article  Google Scholar 

Noon AP, Albertsen PC, Thomas F, Rosario DJ, Catto JWF. Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients. Br J Cancer. 2013;108:1534–40.

Article  CAS  Google Scholar 

Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30:1194–220.

Article  CAS  Google Scholar 

Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432–44.

Article  Google Scholar 

Biganzoli L, Battisti NML, Wildiers H, McCartney A, Colloca G, Kunkler IH, et al. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol. 2021;22:e327–40.

Article  Google Scholar 

Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380:2395–405.

Article  CAS  Google Scholar 

Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717–29.

Article  CAS  Google Scholar 

Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385:2336–47.

Article  CAS  Google Scholar 

Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40:1816–37.

Article  CAS  Google Scholar 

Gendoo DMA, Zon M, Sandhu V, Manem VSK, Ratanasirigulchai N, Chen GM, et al. MetaGxData: clinically annotated breast, ovarian and pancreatic cancer datasets and their use in generating a multi-cancer gene signature. Sci Rep. 2019;9:8770.

Article  ADS  Google Scholar 

Derks MGM, Bastiaannet E, Kiderlen M, Hilling DE, Boelens PG, Walsh PM, et al. Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group. Br J Cancer. 2018;119:121–9.

Article  Google Scholar 

Wildiers H, de Glas NA. Anticancer drugs are not well tolerated in all older patients with cancer. Lancet Healthy Longev. 2020;1:e43–7.

Article  Google Scholar 

Hotta K, Ueoka H, Kiura K, Tabata M, Tanimoto M. An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2004;46:61–76.

Article  Google Scholar 

Tesarova P. Breast cancer in the elderly-Should it be treated differently? Rep Pract Oncol Radiother. 2012;18:26–33.

Article  Google Scholar 

Sanabria A, Carvalho AL, Vartanian JG, Magrin J, Ikeda MK, Kowalski LP. Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol. 2007;14:1449–57.

Article  Google Scholar 

Brain E, Girre V, Rollot F, Bonnetain F, Debled M, Lacroix M, et al. ASTER 70s: benefit of adjuvant chemotherapy for estrogen receptor-positive HER2-negative breast cancer in women over 70 according to genomic grade—A French GERICO/UCBG UNICANCER multicenter phase III trial. J Clin Orthod. 2012;30:TPS667–TPS667.

Google Scholar 

Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–7.

Article  CAS  Google Scholar 

Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98:262–72.

Article  CAS  Google Scholar 

van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6.

Article  Google Scholar 

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.

Article  CAS  Google Scholar 

Tobin NP, Lundberg A, Lindström LS, Harrell JC, Foukakis T, Carlsson L, et al. PAM50 provides prognostic information when applied to the lymph node metastases of advanced breast cancer patients. Clin Cancer Res. 2017;23:7225–31.

Article  CAS  Google Scholar 

Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–7.

Article  Google Scholar 

Wennmalm K, Bergh J. A simple method for assigning genomic grade to individual breast tumours. BMC Cancer. 2011;11:306.

Article  Google Scholar 

Raj-Kumar P-K, Liu J, Hooke JA, Kovatich AJ, Kvecher L, Shriver CD, et al. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B. Sci Rep. 2019;9:7956.

Article  ADS  Google Scholar 

Johansson A, Yu NY, Iftimi A, Tobin NP, van’t Veer L, Nordenskjöld B, et al. Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature. Int J Cancer. 2022;150:2072–82.

Article  CAS  Google Scholar 

Tobin NP, Harrell JC, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, et al. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Ann Oncol. 2015;26:81–8.

Article  CAS  Google Scholar 

Lundberg A, Lindström LS, Harrell JC, Falato C, Carlson JW, Wright PK, et al. Gene expression signatures and immunohistochemical subtypes add prognostic value to each other in breast cancer cohorts. Clin Cancer Res. 2017;23:7512–20.

Article  CAS  Google Scholar 

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111–21.

Article  CAS  Google Scholar 

Kjällquist U, Acs B, Margolin S, Karlsson E, Kessler LE, Garcia Hernandez S, et al. Real world evaluation of the prosigna/PAM50 test in a node-negative postmenopausal Swedish population: a multicenter study. Cancers. 2022. https://doi.org/10.3390/cancers14112615.

Article  Google Scholar 

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93:387–91.

Article  CAS  Google Scholar 

Rueda OM, Sammut S-J, Seoane JA, Chin S-F, Caswell-Jin JL, Callari M, et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature. 2019;567:399–404.

Article  ADS  CAS  Google Scholar 

Buus R, Sestak I, Barron S, Loughman T, Fender B, Ruiz CL, et al. Validation of the OncoMasTR risk score in estrogen receptor-positive/HER2-negative patients: a TransATAC study. Clin Cancer Res. 2020;26:623–31.

Article  CAS  Google Scholar 

Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4:545–53.

Article  Google Scholar 

Brain E, Viansone AA, Bourbouloux E, Rigal O, Ferrero J-M, Kirscher S, et al. Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER HER2- breast cancer and a high genomic grade index: the Unicancer ASTER 70s trial. J Clin Oncol. 2022. https://doi.org/10.1200/jco.2022.40.16_suppl.500.

Article  Google Scholar 

Noordhoek I, Bastiaannet E, de Glas NA, Scheepens J, Esserman LJ, Wesseling J, et al. Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: a population-based cohort study. J Geriatr Oncol. 2022. https://doi.org/10.1016/j.jgo.2022.07.006.

Article  Google Scholar 

Mansani F, Celinski V, Freitas-Junior R. De-escalation of chemotherapy in elderly women using a 70-gene platform: comparison of the MINDACT study with a real-world study in the Brazilian population (AGEMA-BRA). J Clin Orthod. 2022;40:e12568–e12568.

Google Scholar 

Iles K, Roberson ML, Spanheimer P, Gallagher K, Ollila DW, Strassle PD, et al. The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment. npj Breast Cancer. 2022;8:1–8.

Article